Executive Summary
Two-year LANDMARK data show the Myval balloon-expandable transcatheter heart valve continues to match contemporary SAPIEN and Evolut platforms on safety and efficacy, extending the noninferiority signal first reported at 1 year into a window where structural valve deterioration typically declares itself (covered by TCTMD). Sector headlines bundle a fresh Medtronic device recall, FDA clearance of a next-generation valve, and renewed conversation about TAVR drift into younger patients (via Cardiovascular Business). The competitive THV field broadens; the indication creep debate sharpens — which complicates, not settles, the case for transcatheter expansion into patients with decades of expected valve life ahead.
- Myval matches SAPIEN and Evolut on the composite of death, stroke, and valve-related hospitalization at 2 years in LANDMARK (TCTMD).
- Medtronic is recalling thousands of devices as the company heads into June 3 earnings with shares down 25.7% over six months (Cardiovascular Business).
- FDA cleared a next-generation valve and the TAVR-in-younger-patients debate reopened in the same news cycle — an awkward pairing for durability-conscious surgeons (Cardiovascular Business).
- An Edwards CVP sold $2M in EW shares as the stock holds near 52-week highs and Josh Brown re-tagged it a "best stock" pick (Investing.com).
What to watch: Medtronic's June 3 earnings, where Structural Heart commentary on Evolut FX+ uptake and the scope of the current recall will set sector tone heading into summer.
Aortic Valve (TAVR/TAVI)
The LANDMARK 2-year readout extends Myval (Meril Life Sciences) noninferiority versus SAPIEN and Evolut on the composite of death, stroke, and valve-related hospitalization. The 1-year arms overlapped at 87.0% versus 86.9% freedom from events; the 2-year curve, per TCTMD's coverage, continues to track that pattern. A third balloon-expandable option with a credible RCT comparator is relevant for procurement decisions and European operator choice. It is not relevant to the durability question that defines treatment selection for patients under 70. The signal that matters is hemodynamic performance and structural valve deterioration at 5 and 10 years, and LANDMARK isn't there yet. ESC 2025 still recommends SAVR for patients under 70 with low surgical risk (Class I, defined as STS-PROM + EuroSCORE II <4%); ACC/AHA 2020 holds SAVR as the default under 65.
The renewed press attention to "TAVR in younger patients" sits awkwardly against published mid-term data showing patients aged 50–70 with mechanical aortic prostheses outperforming bioprosthetic recipients on long-term survival — with size 19-mm biological valves showing the worst outcomes and severe patient-prosthesis mismatch carrying the lowest survival. A wider THV menu does not change the lifetime-management calculus for a 62-year-old; it changes the marketing.
Regulatory & Policy
Two regulatory threads moved in opposite directions in the same news cycle: FDA cleared a next-generation transcatheter valve, and Medtronic is recalling thousands of devices, per Cardiovascular Business. Device-class scope on the Medtronic recall wasn't broken out in the rollup; clinicians should check the FDA recall database against their current Structural Heart inventory before next week's elective list. The juxtaposition matters: the same regulatory machinery clearing accelerated next-gen approvals is the one issuing the post-market corrections.
Valve Industry Stocks
The 6-month sector chart tells a two-track story: Edwards holding near highs on TAVR concentration and asymptomatic-AS tailwinds, while the diversified med-tech names (MDT, ABT, BSX) take meaningful damage on broader market and company-specific drag. Anteris is the speculative outlier, up nearly 99% on DurAVR momentum.
Edwards Lifesciences (EW)
- Close: $85.96, down $0.55 (-0.64%) on the day
- 6-month: +0.81%; 52-week range $72.30–$88.28 (trading near the top)
- Market cap $49.5B; trailing P/E 46.46, forward P/E 25.54; beta 0.87
- Analyst target $97.15 (range $84–$110, 27 analysts); consensus buy
- Next earnings July 23 (EPS est $0.74, revenue est $1.70B)
Edwards outperforms its peer set on the strength of a pure-play TAVR/TMTT story. Josh Brown re-tagged the name a "best stock" pick this week (CNBC), and EARLY TAVR's positive readout keeps the indication-expansion thesis intact. Counter-signal: CVP Donald Bobo Jr. sold $2M in stock (Investing.com) with shares at the top of the range — routine for executives at peaks, but worth logging.
Medtronic (MDT)
- Close: $75.57, down $0.41 (-0.54%) on the day
- 6-month: -25.73%; sitting near 52-week low of $74.40
- Market cap $97.0B; trailing P/E 21.11, forward P/E 12.47; beta 0.63
- Analyst target $107.08 (range $84–$121, 26 analysts); consensus buy
- Next earnings June 3 (EPS est $1.55, revenue est $9.61B)
MDT enters its June 3 print at the bottom of its range, weighed by a device recall this week (Cardiovascular Business) and broader diversified-portfolio multiple compression. Forward P/E of 12.47 versus EW's 25.54 quantifies the gap the market is pricing between pure-play structural heart and diversified med-tech. Structural Heart commentary on the call will be the leveraged read for the sector.
Abbott (ABT)
- Close: $86.30, up $0.62 (+0.72%) on the day
- 6-month: -31.82%; near 52-week low
- Market cap $150.3B; trailing P/E 24.17, forward P/E 14.24; beta 0.65
- Analyst target $118.32 (range $92–$143, 25 analysts); consensus buy
- Next earnings July 16 (EPS est $1.28, revenue est $12.53B)
Abbott's six-month drawdown is not a Structural Heart story — TriClip and MitraClip remain the franchise's clinical anchors, with ESC 2025 elevating TEER for ventricular SMR to Class I and transcatheter tricuspid therapy to Class IIa. The pressure is broader-portfolio. Watch the diagnostics and nutrition lines into July; TriClip volumes will quietly compound.
Boston Scientific (BSX)
- Close: $49.11, down $1.35 (-2.68%) on the day
- 6-month: -51.38%; at 52-week low of $48.41
- Market cap $73.0B; trailing P/E 20.55, forward P/E 13.11; beta 0.62
- Analyst target $80.16 (range $55–$106, 32 analysts); consensus strong buy
- Next earnings July 29 (EPS est $0.83, revenue est $5.38B)
BSX has halved over six months — the largest decline in the peer set. ACURATE neo2's withdrawal from the US market following the failed ACURATE IDE trial removed the company's near-term TAVR optionality; the structural heart story now rests on the WATCHMAN franchise and adjacencies. Strong-buy consensus with shares at the 52-week low is the analyst community calling a floor, not endorsing the trajectory.
Anteris Technologies (AVR.AX)
- Close: A$12.27, up A$0.29 (+2.42%) on the day
- 6-month: +98.87%; at 52-week high
- Market cap A$1.2B; forward P/E -5.63 (pre-revenue); beta 0.59
- Single analyst target A$13.00
DurAVR's single-piece bioprosthetic design is the most-watched novel-leaflet story in the field, but Anteris remains a clinical-stage company with binary trial risk. A near-doubling on early data is the market pricing optionality, not durability.
Market outlook: Pure-play structural heart commands a premium; diversified med-tech is being repriced on portfolio risk. MDT's June 3 print is the next inflection — Structural Heart segment growth, Evolut FX+ commentary, and the recall's quantified financial impact will set the tone for the July reporting cycle when EW, ABT, and BSX follow.
Next inflection: Medtronic earnings Tuesday, then PCR London Valves and the late-summer push toward TCT, where Myval LANDMARK 3-year data, additional DEDICATE follow-up, and TRISCEND II durability updates will press on the indication-expansion question this week's headlines politely sidestepped.